



Response Under 37 C.F.R. 1.116
Expedited Procedure
Examining Group: 1811

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: D. DeFeo-Jones et al.

Serial No.: 08/468,161 **Case No.:** 19253IB

Filed: June 6, 1995

For: NOVEL PEPTIDES

Art Unit:
1811

Examiner:
S. Marshall

The Honorable Assistant Commissioner for Patents
Box AF
Washington, D.C. 20231

OCT 29 1997

AMENDMENT UNDER 37 C.F.R. 1.116

Sir:

The following amendments and remarks are in response to the Office Action that was dated August 5, 1997, which was made final and for which a response is due on November 5, 1997. Please amend the application as follows:

In the Claims:

Cancel Claim 12 and rewrite it as new Claim 21:

B1 1 - - 21. A conjugate which is useful for the treatment of prostate cancer, which comprises a cytotoxic agent attached to an oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen and provided that the oligopeptide does not comprise semenogelin I or semenogelin II, wherein the means of attachment is a covalent bond or a chemical linker. - -

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By G. Emerick Date 10-24-97